The Physical Properties of Rectal Contents Have Effects on Anorectal Continence: Insights From a Study Into the Cause of Fecal Spotting on Orlistat
Authors:
- Werner SchwizerWSWerner Schwizer
- Dieter MenneDMDieter Menne
- Bernadette StutzBSBernadette Stutz
- Michael FriedMFMichael Fried
- Miriam ThumshirnMTMiriam Thumshirn
- 1 December 2004
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Diseases of the Colon & Rectum
- Vol. 47 (12) , 2147-2156
Abstract
The intermittent loss of oil or stool (“spotting”) is an adverse effect that occurs in patients taking orlistat; the pathophysiology is unknown. This study was designed to investigate the local effects of orlistat, free fatty acids, and the effects of the physical properties of rectal contents on anorectal function and continence. Anorectal physiology and continence function were assessed in ten healthy patients after the application of four test enemas: 1) high-viscosity stool substitute, 2) stool substitute with free fatty acid, 3) low-viscosity oil with placebo, 4) oil with orlistat. Rectal function and capacity were assessed by barostat techniques. Anal resting pressure, squeeze pressure, and squeeze duration were assessed by manometry. A retention test was performed using the same enemas as a quantitative assessment of continence. Orlistat and free fatty acid had no adverse effects on anorectal function or continence. For each enema, the maximum volume retained correlated with rectal capacity (r= 0.85;P< 0.01). Continence during rectal filling was better maintained for high-viscosity stool substitute than low-viscosity oil enemas (P< 0.03). Patients able to maintain effective squeeze pressure retained more of the low-viscosity enemas than those with short squeeze duration (P< 0.01); in contrast, the volume retained of high-viscosity enemas was unaffected by anal sphincter function. The physical properties of rectal contents, rectal capacity, and voluntary anal sphincter function have effects on continence function in healthy patients. The occurrence of spotting may depend on both intrinsic anorectal function and the effects of orlistat on the volume and physical properties of stool.Keywords
This publication has 20 references indexed in Scilit:
- The pathophysiology of faecal spotting in obese subjects during treatment with orlistatAlimentary Pharmacology & Therapeutics, 2004
- Weight Control and Risk Factor Reduction in Obese Subjects Treated for 2 Years With OrlistatJAMA, 1999
- Rectal tone, distensibility, and perception: reproducibility and response to different distensionsAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 1998
- Standardization of Barostat Procedures for Testing Smooth Muscle Tone and Sensory Thresholds in the Gastrointestinal TractDigestive Diseases and Sciences, 1997
- Review of Limited Systemic Absorption of Orlistat, a Lipase Inhibitor, in Healthy Human VolunteersThe Journal of Clinical Pharmacology, 1995
- Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteersClinical Pharmacology & Therapeutics, 1994
- Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18–0647 (tetrahydrolipstatin)The American Journal of Clinical Nutrition, 1992
- The effect of stool consistency on rectal and neorectal emptyingDiseases of the Colon & Rectum, 1991
- Effect of stool size and consistency on defecation.Gut, 1987
- Decreased fluid tolerance, accelerated transit, and abnormal motility of the human colon induced by oleic acidGastroenterology, 1986